The FDA said it would re-examine the company's only drug sending shares tumbling. : Point72 Chairman and CEO Steven Cohen has increased his position in Acadia Pharmaceuticals, a developer of treatments targeting central nervous system disorders, by 45.6% as the price dropped, GuruFocus Real Time Picks data showed Tuesday. Cohen’s purchase consisted of 1,987,174 shares and raised his aggregate holding to 6,344,600 shares, giving him a 5.08% stake in the company. His execution price around $16 on June 15 was substantially below the stock’s first-quarter average price of $28 due to a 46% plunge year to date.